Abstract:Lan Sun, 1 Hong-Juan Yao, 2 Jing-Cao Li, 1 Bao-Quan Zhao, 1 Yong-An Wang, 1 Ying-Ge Zhang 1 1 Key Laboratory of Nanopharmacology and Nanotoxicology, Beijing Institute of Pharmacology and Toxicology, Beijing, People's Republic of China; 2 Key Laboratory of Antibiotic Bioengineering of National Health and Family Planning Commission (NHFPC), Institute of Medicinal Biotechnology (IMB), Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, People's Republic of China Correspondence: Ying-Ge Zhang; Yong-An Wang, Beijing Institute of Pharmacology and Toxicology, Beijing, People's Republic of China, Tel +86 10-66930654 ; +86 10-66874607, Fax +86 10-68211656, Email ; Introduction: Hepatocellular cancer stem cells (CSCs) play crucial roles in hepatocellular cancer initiation, development, relapse, and metastasis. Therefore, eradication of this cell population is a primary objective in hepatocellular cancer therapy. We prepared a nanodrug delivery system with activated carbon nanoparticles (ACNP) as carriers and metformin (MET) as drug (ACNP-MET), which was able to selectively eliminate hepatocellular CSCs and thereby increase the effects of MET on hepatocellular cancers. Methods: ACNP were prepared by ball milling and deposition in distilled water. Suspension of ACNP and MET was mixed and the best ratio of ACNP and MET was determined based on the isothermal adsorption formula. Hepatocellular CSCs were identified as CD133 + cells and cultured in serum-free medium. We investigated the effects of ACNP-MET on hepatocellular CSCs, including the inhibitory effects, the targeting efficiency, self-renewal capacity, and the sphere-forming capacity of hepatocellular CSCs. Next, we evaluated the therapeutic efficacy of ACNP-MET by using in vivo relapsed tumor models of hepatocellular CSCs. Results: The ACNP have a similar size, a regular spherical shape and a smooth surface. The optimal ratio for adsorption was MET: ACNP=1:4. ACNP-MET could target and inhibit the proliferation of CD133 + population and decrease mammosphere formation and renewal of CD133 + population in vitro and in vivo. Conclusion: These results not only suggest that nanodrug delivery system increased the effects of MET, but also shed light on the mechanisms of the therapeutic effects of MET and ACNP-MET on hepatocellular cancers. ACNP, as a good nano-carrier, could strengthen the effect of MET by carrying drugs to the micro-environment of hepatocellular CSCs. Keywords: nanodrug delivery system, metformin, CD133, hepatocellular cancer stem cells Hepatocellular cancer is the third leading cause of cancer death worldwide and its incidence is increasing. 1–4 While better detection methods and treatment of hepatocellular cancer have improved disease outcomes at early stages, hepatocellular cancer remains largely incurable due to high recurrence rates and resistance to chemotherapy. 5,6 According to the cancer stem cell (CSC) hypothesis, CSCs, which are similar to normal adult stem cells, are at the germinal center of tumors, have the potential of differentiation and self-renewal. 7 Recently, increasing attention has been focused on better explanation of the initiation of relapse and metastasis in several types of carcinomas including hepatocellular cancers. 8,9 CSCs are able to differentiate into specific progeny which can initiate and maintain tumor growth. 10 It is believed that they could be a source for drug resistance, tumor recurrence, and metastasis. 11 These CSCs have been found in hepatocellular cancers with tumorigenicity and chemoresistance to CD133, which has been identified as an important marker of hepatocellular CSCs. 3 CD133 + cells are proliferative, as evidenced by their high colony-forming efficiency. 12 Previous research demonstrated that CD133 + cells originating from Huh-7 cells were more proliferative and possessed higher tumorigenic potential than their CD133 − counterparts. 13 By immunohistochemistry, CD133 expression and elevated CD133 expression were associated with advanced tumor grade and elevated serum alpha-fetoprotein levels. In addition, patients with higher CD133 ratio in their tumors had shorter survival period and higher relapse rates compared with low CD133 patients. Multivariate analyses showed that increased CD133 expression was an independent prognostic factor for survival and tumor recurrence. 14 Therefore, the number of CD133 + cells in hepatocellular cancer represents a key prognostic marker for hepatocellular cancer. Metformin (MET), a traditional -Abstract Truncated-

Metformin-Loaded Hyaluronic Acid-Derived Carbon Dots for Targeted Therapy against Hepatocellular Carcinoma by Glutamine Metabolic Reprogramming

Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy

Metabolic reprogramming enables hepatocarcinoma cells to efficiently adapt and survive to a nutrient-restricted microenvironment

A Convergent Synthetic Platform for Dual Anticancer Drugs Functionalized by Reduced Graphene Nanocomposite Delivery for Hepatocellular Cancer.

Metformin Induces Autophagy via the AMPK-mTOR Signaling Pathway in Human Hepatocellular Carcinoma Cells

Activated Carbon nanoparticles Loaded with Metformin for Effective Against Hepatocellular Cancer Stem Cells

Reprogramming Of Glucose Metabolism For Revisiting Hepatocellular Carcinoma Resistance To Transcatheter Hepatic Arterial Chemoembolization

Hyaluronic acid-based multifunctional nanoplatform for glucose deprivation-enhanced chemodynamic/photothermal synergistic cancer therapy

Carbonized polymer dots derived from metformin and L-arginine for tumor cell membrane- and mitochondria-dual targeting therapy

The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy In Hepatocellular Carcinoma Cells

AMPK-Mediated Metabolic Switching Is High Effective for Phytochemical Levo-Tetrahydropalmatine (l-THP) to Reduce Hepatocellular Carcinoma Tumor Growth

Targeting Metabolic Reprogramming in Hepatocellular Carcinoma to Overcome Therapeutic Resistance: A Comprehensive Review

Dual-molecular targeting nanomedicine upregulates synergistic therapeutic efficacy in preclinical hepatoma models

Caffeic Acid Expands Anti-Tumor Effect of Metformin in Human Metastatic Cervical Carcinoma HTB-34 Cells: Implications of AMPK Activation and Impairment of Fatty Acids De Novo Biosynthesis

Targeting Tumor Energy Metabolism Via Simultaneous Inhibition of Mitochondrial Respiration and Glycolysis Using Biodegradable Hydroxyapatite Nanorods

Highly Biocompatible Thermosensitive Nanocomposite Gel for Combined Therapy of Hepatocellular Carcinoma Via the Enhancement of Mitochondria Related Apoptosis

Metformin and histone deacetylase inhibitor based anti-inflammatory nanoplatform for epithelial-mesenchymal transition suppression and metastatic tumor treatment

The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance

Repurposing mitochondrial-targeting anthelmintic agents with GLUT1 inhibitor BAY-876 for cancer therapy

Hyaluronic Acid Conjugated Metformin-Phospholipid Sonocomplex: A Biphasic Complexation Approach to Correct Hypoxic Tumour Microenvironment

The anticancer effect of metformin targets VDAC1 via ER-mitochondria interactions-mediated autophagy in HCC